242 related articles for article (PubMed ID: 28317660)
1. Safety, tolerability and efficacy of intradermal rabies immunization with DebioJect™.
Vescovo P; Rettby N; Ramaniraka N; Liberman J; Hart K; Cachemaille A; Piveteau LD; Zanoni R; Bart PA; Pantaleo G
Vaccine; 2017 Mar; 35(14):1782-1788. PubMed ID: 28317660
[TBL] [Abstract][Full Text] [Related]
2. A single center, open label study of intradermal administration of an inactivated purified chick embryo cell culture rabies virus vaccine in adults.
Recuenco S; Warnock E; Osinubi MOV; Rupprecht CE
Vaccine; 2017 Aug; 35(34):4315-4320. PubMed ID: 28688782
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of novel dermal and epidermal microneedle delivery systems for rabies vaccination in healthy adults.
Laurent PE; Bourhy H; Fantino M; Alchas P; Mikszta JA
Vaccine; 2010 Aug; 28(36):5850-6. PubMed ID: 20600481
[TBL] [Abstract][Full Text] [Related]
4. Rabies neutralizing antibody after 2 intradermal doses on days 0 and 21 for pre-exposure prophylaxis.
Wongsaroj P; Udomchaisakul P; Tepsumethanon S; Khawplod P; Tantawichien T
Vaccine; 2013 Mar; 31(13):1748-51. PubMed ID: 23370149
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial.
Alberer M; Gnad-Vogt U; Hong HS; Mehr KT; Backert L; Finak G; Gottardo R; Bica MA; Garofano A; Koch SD; Fotin-Mleczek M; Hoerr I; Clemens R; von Sonnenburg F
Lancet; 2017 Sep; 390(10101):1511-1520. PubMed ID: 28754494
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a new purified vero cell rabies vaccine (PVRV) administered by intramuscular and intradermal routes in healthy volunteers.
Kulkarni PS; Sapru A; D'costa PM; Pandit A; Madhusudana SN; Yajaman AB; Mangrule S; Gunale B; Bavdekar AR
Vaccine; 2013 May; 31(24):2719-22. PubMed ID: 23583817
[TBL] [Abstract][Full Text] [Related]
7. Comparative study on the immunogenicity and safety of a purified chick embryo cell rabies vaccine (PCECV) administered according to two different simulated post exposure intramuscular regimens (Zagreb versus Essen).
Mahendra BJ; Narayana DA; Agarkhedkar S; Ravish HS; Harish BR; Agarkhedkar S; Madhusudana SN; Belludi A; Ahmed K; Jonnalagedda R; Vakil H; Bhusal C; Arora AK
Hum Vaccin Immunother; 2015; 11(2):428-34. PubMed ID: 25692792
[TBL] [Abstract][Full Text] [Related]
8. A randomized open-labeled study to demonstrate the non-inferiority of purified chick-embryo cell rabies vaccine administered in the Zagreb regimen (2-1-1) compared with the Essen regimen in Chinese adults.
Ma J; Wang H; Li J; Chang L; Xie Y; Liu Z; Zhao Y; Malerczyk C
Hum Vaccin Immunother; 2014; 10(10):2805-12. PubMed ID: 25483635
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of purified chick-embryo cell rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese children 6 to 17 years old and adults over 50 years: a randomized open-label study.
Li R; Li Y; Wen S; Wen H; Nong Y; Mo Z; Xie F; Pellegrini M
Hum Vaccin Immunother; 2015; 11(2):435-42. PubMed ID: 25692350
[TBL] [Abstract][Full Text] [Related]
10. A randomized non-inferiority clinical study to assess post-exposure prophylaxis by a new purified vero cell rabies vaccine (Rabivax-S) administered by intramuscular and intradermal routes.
Bose A; Munshi R; Tripathy RM; Madhusudana SN; Harish BR; Thaker S; Mahendra BJ; Gunale B; Gogtay NJ; Thatte UM; Mani RS; Manjunath K; George K; Yajaman AB; Sahai A; Dhere RM; Alex RG; Adhikari DD; Abhilash ; Raghava V; Kumbhar D; Behera TR; Kulkarni PS
Vaccine; 2016 Sep; 34(40):4820-6. PubMed ID: 27554534
[TBL] [Abstract][Full Text] [Related]
11. Serologic Response of 2 Versus 3 Doses and Intradermal Versus Intramuscular Administration of a Licensed Rabies Vaccine for Preexposure Prophylaxis.
Endy TP; Keiser PB; Wang D; Jarman RG; Cibula D; Fang H; Ware L; Abbott M; Thomas SJ; Polhemus ME
J Infect Dis; 2020 Apr; 221(9):1494-1498. PubMed ID: 31802120
[TBL] [Abstract][Full Text] [Related]
12. Making rabies prophylaxis more economical: immunogenicity and safety results from a preliminary study using a 2-1 intramuscular regimen in healthy volunteers.
Huang G; Liu H; Tang Q; Yu P; Shen X; Zhang Y; Liu X; Cao Q; Fu C; Liu B; Wang M
Hum Vaccin Immunother; 2014; 10(1):114-9. PubMed ID: 24008819
[TBL] [Abstract][Full Text] [Related]
13. A next-generation, serum-free, highly purified Vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab® when administered according to a post-exposure regimen in healthy children and adults in China.
Li R; Huang L; Li J; Mo Z; He B; Wang Y; Wu X; Minutello M; Guinet-Morlot F; Pichon S
Vaccine; 2013 Dec; 31(50):5940-7. PubMed ID: 24148575
[TBL] [Abstract][Full Text] [Related]
14. Comparative Immunogenicity and Safety Trial of 2 Different Schedules of Single-visit Intradermal Rabies Postexposure Vaccination.
Soentjens P; De Koninck K; Tsoumanis A; Herssens N; Van Den Bossche D; Terryn S; Van Gucht S; Van Damme P; Van Herrewege Y; Bottieau E
Clin Infect Dis; 2019 Aug; 69(5):797-804. PubMed ID: 30566636
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety study of Indirab: a Vero cell based chromatographically purified human rabies vaccine.
Sampath G; Madhusudana SN; Sudarshan MK; Ashwathnarayana DH; Mahendra BJ; Ullas TP; Mohan K; Madhusudhan SK; Ravish HS
Vaccine; 2010 May; 28(24):4086-90. PubMed ID: 20403351
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity study of a new purified chick embryo cell rabies vaccine Vaxirab-N (Pitman-Moore strain) manufactured in India.
Ashwath Narayana DH; Madhusudana SN; Sampath G; Tripathy RM; Sudarshan MK; Gangaboraiah ; Ravish HS; Satapathy DM; Gowda G; Holla R; Ashwin BY; Padhi A; Manjula S; Patel PM
Hum Vaccin Immunother; 2014; 10(1):120-5. PubMed ID: 24030586
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of chromatographically purified Vero cell rabies vaccine for intradermal pre- and post-exposure rabies prophylaxis.
Tantawichien T; Sibunruang S; Tantawichien T; Angsanakul J; Benjavongkulchai M; Limsuwan K; Udomchaisakul P; Khomvilai S; Sitprija V
Expert Rev Vaccines; 2014 Dec; 13(12):1593-601. PubMed ID: 25315021
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of a reduced-dose whole killed rabies vaccine is significantly enhanced by ISCOMATRIX™ adjuvant, Merck amorphous aluminum hydroxylphosphate sulfate (MAA) or a synthetic TLR9 agonist in rhesus macaques.
DiStefano D; Antonello JM; Bett AJ; Medi MB; Casimiro DR; ter Meulen J
Vaccine; 2013 Oct; 31(42):4888-93. PubMed ID: 23941913
[TBL] [Abstract][Full Text] [Related]
19. Preexposure Intradermal Rabies Vaccination: A Noninferiority Trial in Healthy Adults on Shortening the Vaccination Schedule From 28 to 7 Days.
Soentjens P; Andries P; Aerssens A; Tsoumanis A; Ravinetto R; Heuninckx W; van Loen H; Brochier B; Van Gucht S; Van Damme P; Van Herrewege Y; Bottieau E
Clin Infect Dis; 2019 Feb; 68(4):607-614. PubMed ID: 29939243
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age.
Gorse GJ; Falsey AR; Johnson CM; Morrison D; Fried DL; Ervin JE; Greenberg DP; Ozol-Godfrey A; Landolfi V; Tsang PH
Vaccine; 2013 Dec; 31(50):6034-40. PubMed ID: 24055306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
